The AHF-CORE study is a prospective, non-randomized, multicenter regional study. The main objective of the AHF-CORE study is to identify congestion markers (clinical, biological and ultrasound) at the beginning and at the end of hospitalization for acute heart failure that are more strongly associated with the risk of all cause death or rehospitalization for acute heart failure within 3 months of hospital discharge. Secondary objectives are: * Quantify the variations in congestion markers between the beginning and end of hospitalization for acute heart failure. * Assess the correlation between changes in congestion markers between the beginning and end of hospitalization. * Identify the congestion markers at the beginning of hospitalization that are most strongly associated with residual congestion at the end of hospitalization. * Identify the added value of ultrasound and biological markers of congestion in addition to clinical variables for the prediction of all-cause death or hospitalization for acute heart failure at 3 months after hospital discharge. * Identify the association of ultrasound and biologic congestion markers assessed at admission and final discharge with NYHA class at 3 months after hospital discharge
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of all-cause death
Timeframe: at 3 months after hospital discharge
Rate of rehospitalization for acute heart failure
Timeframe: at 3 months after hospital discharge
Rate of day-hospital or at-home IV diuretics injection for acute HF
Timeframe: at 3 months after hospital discharge